SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
BioMidwest
Report: Projected Sales of 10 Top-Selling Drugs Through 2024
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
August 16, 2019
 · 
3 min read
 · 
Mark Terry
What Brent Saunders Thinks About a Possible Allerg
Business
After AbbVie Acquisition, Allergan’s Saunders Can Walk Away with $39 Million
According to a regulatory filing, Saunders will walk away with $14.9 million in cash and $23.6 million in equity, mostly stock based on performance.
August 15, 2019
 · 
3 min read
 · 
Mark Terry
Job Trends
Top Life Science Companies Hiring Now in August
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!
August 5, 2019
 · 
1 min read
 · 
Editorial Staff
BioMidwest
AbbVie Raises 2019 Profit Target Amid Sliding Global Humira Sales
Sales of Humira slid in Europe as AbbVie’s cash cow continues to face competition from biosimilars that became available at the end of last year.
July 26, 2019
 · 
3 min read
 · 
Alex Keown
FDA
FDA Approves Samsung Bioepis’ Humira Biosimilar
Despite the approval, Samsung Bioepis’ Hadlima will not be available in the U.S. until 2023, due to licensing deals with AbbVie, the maker of Humira.
July 24, 2019
 · 
2 min read
 · 
Alex Keown
A Dozen Biopharma Companies Land On Fortune 500 List
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
July 23, 2019
 · 
4 min read
 · 
Alex Keown
mrinalpal / Shutterstock
BioForest
Certified Great Places to Work By BioSpace Hotbed Regions
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regions. Take a look.
July 17, 2019
 · 
5 min read
 · 
Mark Terry
Business
AbbVie Dives into STING and Boehringer Ingelheim Snaps Up Swiss-based AMAL
The M&A moves are expected to increase the oncology pipelines of both companies.
July 15, 2019
 · 
3 min read
 · 
Alex Keown
Business
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
CytomX Therapeutics, Inc. announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates.
July 9, 2019
 · 
5 min read
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Business
AbbVie Calls on Students with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2021-2022 Academic School Year
March 17, 2021
 · 
4 min read
BioMidwest
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis
March 17, 2021
 · 
8 min read
Deals
Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie
February 28, 2021
 · 
2 min read
FDA
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
February 24, 2021
 · 
14 min read
BioMidwest
New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
February 23, 2021
 · 
3 min read
Drug Development
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
February 22, 2021
 · 
17 min read
Policy
AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
February 19, 2021
 · 
2 min read
BioMidwest
AbbVie to Present at the Cowen 41st Annual Health Care Conference
February 19, 2021
 · 
1 min read
BioMidwest
AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 12, 2021
 · 
1 min read
Business
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
February 10, 2021
 · 
5 min read
Load More